BR9909876A - Composições farmacêuticas para tratamento, melhoria ou prevenção da isquemia, respectivos métodos e usos - Google Patents
Composições farmacêuticas para tratamento, melhoria ou prevenção da isquemia, respectivos métodos e usosInfo
- Publication number
- BR9909876A BR9909876A BR9909876-8A BR9909876A BR9909876A BR 9909876 A BR9909876 A BR 9909876A BR 9909876 A BR9909876 A BR 9909876A BR 9909876 A BR9909876 A BR 9909876A
- Authority
- BR
- Brazil
- Prior art keywords
- ischemia
- seq
- prevention
- improvement
- treatment
- Prior art date
Links
- 208000028867 ischemia Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 108700040992 Ala(2)- deltorphin I Proteins 0.000 abstract 1
- 108700040991 Ala(2)- deltorphin II Proteins 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 101800005209 Deltorphin Proteins 0.000 abstract 1
- BHSURCCZOBVHJJ-NWOHMYAQSA-N Deltorphin A Chemical compound C([C@H](N)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(N)=O)C1=CC=C(O)C=C1 BHSURCCZOBVHJJ-NWOHMYAQSA-N 0.000 abstract 1
- NUNBRHVOPFWRRG-RCEFDBTISA-N Deltorphin B Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(N)=O)C(C)C)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 NUNBRHVOPFWRRG-RCEFDBTISA-N 0.000 abstract 1
- CJAORFIPPWIGPG-QXYJMILXSA-N Deltorphin C Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(=O)NCC(N)=O)C(C)C)NC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 CJAORFIPPWIGPG-QXYJMILXSA-N 0.000 abstract 1
- 208000036982 Spinal cord ischaemia Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
<B>COMPOSIçõES FARMACêUTICAS PARA TRATAMENTO, MELHORIA OU PREVENçãO DA ISQUEMIA, RESPECTIVOS MéTODOS E USOS<D> Método de tratamento de isquemia por administração de deltorfinas a um mamífero. Podem ser administradas a deltorfina I SEQ ID NO:1, a deltorfina II SEQ ID NO:2 ou uma combinação de deltorfinas I SEQ ID NO:1 e II SEQ ID NO:2. Uma concentração de deltorfina de cerca de 0,5-20mg/kg ou alternativamente 1-1000<109>g/kg de peso corpóreo do mamífero em formulação fisiologicamente aceitável é administrada até quatro horas após um episódio isquêmico. As deltorfinas podem também ser administradas antes ou concorrentemente ao início da isquemia. A isquemia cerebral ou da medula espinhal ou doença cardíaca isquêmica pode ser tratada usando o método da invenção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7123698A | 1998-05-01 | 1998-05-01 | |
| PCT/US1999/009452 WO1999056766A2 (en) | 1998-05-01 | 1999-04-30 | Method for treating ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9909876A true BR9909876A (pt) | 2000-12-19 |
Family
ID=22100105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9909876-8A BR9909876A (pt) | 1998-05-01 | 1999-04-30 | Composições farmacêuticas para tratamento, melhoria ou prevenção da isquemia, respectivos métodos e usos |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1073451B1 (pt) |
| JP (1) | JP2003522727A (pt) |
| AT (1) | ATE220330T1 (pt) |
| AU (1) | AU756200B2 (pt) |
| BR (1) | BR9909876A (pt) |
| CA (1) | CA2325387A1 (pt) |
| DE (1) | DE69902096T2 (pt) |
| MX (1) | MXPA00010616A (pt) |
| NZ (1) | NZ507523A (pt) |
| WO (1) | WO1999056766A2 (pt) |
| ZA (1) | ZA200005920B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900178B2 (en) | 2000-09-12 | 2005-05-31 | University Of Kentucky Research Foundation | Protection against ischemia and reperfusion injury |
| US6875742B2 (en) | 2000-10-10 | 2005-04-05 | Zymogenetics, Inc. | Method for treating cytokine mediated hepatic injury |
| US6645938B2 (en) * | 2000-10-10 | 2003-11-11 | Zymogenetics, Inc. | Protection against ischemia and reperfusion injury |
| EP1572168B1 (en) | 2002-02-06 | 2010-05-26 | Vicor Technologies, Inc. | Anti-infarction molecules |
| EP2286731B1 (en) | 2003-10-17 | 2012-05-09 | Tyco Healthcare Group LP | Surgical stapling device |
| US7705119B1 (en) | 2007-04-09 | 2010-04-27 | University Of Kentucky Research Foundation | Compositions and methods useful for treating circulatory and hypovolemic shock |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656420A (en) * | 1995-02-24 | 1997-08-12 | University Of Kentucky Research Foundation | Method for employing the delta opioid dadle to extend tissue survival time during ischemia |
-
1999
- 1999-04-30 MX MXPA00010616A patent/MXPA00010616A/es unknown
- 1999-04-30 BR BR9909876-8A patent/BR9909876A/pt not_active Application Discontinuation
- 1999-04-30 AT AT99920203T patent/ATE220330T1/de not_active IP Right Cessation
- 1999-04-30 EP EP99920203A patent/EP1073451B1/en not_active Expired - Lifetime
- 1999-04-30 NZ NZ507523A patent/NZ507523A/xx unknown
- 1999-04-30 JP JP2000546790A patent/JP2003522727A/ja active Pending
- 1999-04-30 WO PCT/US1999/009452 patent/WO1999056766A2/en not_active Ceased
- 1999-04-30 CA CA002325387A patent/CA2325387A1/en not_active Abandoned
- 1999-04-30 AU AU37758/99A patent/AU756200B2/en not_active Ceased
- 1999-04-30 DE DE69902096T patent/DE69902096T2/de not_active Expired - Fee Related
-
2000
- 2000-10-23 ZA ZA200005920A patent/ZA200005920B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE220330T1 (de) | 2002-07-15 |
| JP2003522727A (ja) | 2003-07-29 |
| NZ507523A (en) | 2002-09-27 |
| AU3775899A (en) | 1999-11-23 |
| EP1073451A3 (en) | 2003-06-04 |
| ZA200005920B (en) | 2003-03-05 |
| DE69902096T2 (de) | 2003-02-27 |
| WO1999056766A2 (en) | 1999-11-11 |
| WO1999056766A3 (en) | 2003-04-17 |
| AU756200B2 (en) | 2003-01-09 |
| EP1073451A2 (en) | 2001-02-07 |
| MXPA00010616A (es) | 2002-07-02 |
| DE69902096D1 (de) | 2002-08-14 |
| EP1073451B1 (en) | 2002-07-10 |
| CA2325387A1 (en) | 1999-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10323240B2 (en) | Compositions and methods of using chondroitinase ABCI mutants | |
| KR102372194B1 (ko) | Lsd1 억제제를 이용한 다발성 경화증의 치료방법 | |
| Webb et al. | Spinal cord injury I: A synopsis of the basic science | |
| KR100951540B1 (ko) | 탈수초성 질병 또는 상태 치료용 약제학적 조성물 | |
| WO2003034996B1 (en) | Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment | |
| WO2004087141B1 (en) | Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases | |
| BR9909876A (pt) | Composições farmacêuticas para tratamento, melhoria ou prevenção da isquemia, respectivos métodos e usos | |
| Lee et al. | Dexfenfluramine as a mitogen signals through the formation of superoxide anion | |
| NZ329407A (en) | Use of dopamine d2 receptor antagonists to promote follicular growth, ovulation, parturition or lactation in mammals | |
| EP0305181A2 (en) | Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin | |
| KR20220110278A (ko) | 타우병증을 치료하기 위한 펩타이드 조성물 및 방법 | |
| Grobecker et al. | Effect of prolonged treatment with adrenergic neuron blocking drugs on sympathoadrenal reactivity in rats | |
| CN106377764A (zh) | 重组人Prx‑6蛋白在治疗烧烫伤方面的用途 | |
| Gyarfas et al. | Central inhibitory effects of carbon dioxide. IV. Convulsive phenomena | |
| JPWO2004035053A1 (ja) | 神経栄養因子産生促進剤 | |
| Yoshida et al. | Effects of compound 48/80 and exogenous histamine on wound healing in mice | |
| KR100782333B1 (ko) | 혈장 또는 혈청을 포함하는 신경손상 치료용 약학 조성물 | |
| Li et al. | Calcium channels mediate mechanically induced bone adaptation in vivo | |
| ME01259B (me) | Nova terapeutska upotreba adrenergičkog alfuzosina | |
| Jackson | Barbara Stauch Slusher, Paul F. Jackson, and Lisa A. Arvanitis | |
| KR19990069591A (ko) | 성기능 장애 치료제 및 치료방법 | |
| HK1018745B (en) | Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction | |
| HK1018745A1 (en) | Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |